Skip to content
Screener

Discontinued — last reported Q1 '25

D&A at other companies

West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
$46.2M+11.6%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$4.5M+66.7%
Ashland logo
AshlandASH
$48M-36.8%
KORU Medical Systems logo
KORU Medical SystemsKRMD
$210.03K+0.3%
IR
Ingersoll RandIR
$102.6M+12.0%
Baxter International logo
Baxter InternationalBAX
$237M-4.0%

Segments

By segment

See full
Pharma$35.64M+14.4%
Beauty$24.72M+23.2%
Closures$14.22M+4.8%

Other financials

Income statement

See full
Revenue$982.9M+10.8%
Gross profit$351.9M+4.6%
Operating income$107.5M-5.2%
Net income$72.7M-7.8%
EPS (diluted)$1.12-4.3%

Balance sheet

See full
Cash & equivalents$225.0M+78.8%
Total debt$1.4B+32.7%
Total equity$2.6B+3.6%
Total assets$5.1B+12.6%

Cash flow

See full
Operating cash flow$118.7M+43.5%
CapEx$65.4M+15.0%
Free cash flow$53.3M+106%

Valuation

See full
Market cap$8.69B-4.7%
Enterprise value$9.9B-2.2%
P/E22.5×-0.8×
P/S2.3×-0.3×

Profitability

See full
Gross margin36.7%-1.6pp
Operating margin12.8%-1.2pp
Net margin10%-0.4pp
FCF margin8.4%-2.1pp

Returns & leverage

See full
Return on equity15%-0.2pp
Debt / equity0.5×+0.1×
Current ratio1.7×+0.4×

Where this comes from

Reported directly by AptarGroup in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The source filing: AptarGroup’s 10-Q, filed May 2, 2025.

Filed
May 2, 2025
Fiscal quarter
Q1 FY2025
Calendar quarter
Q1 2025
Accession
0000896622-25-000014
In thousands, except per share amounts / Three Months Ended March 31,20252024
Operating Expenses:
Cost of sales (exclusive of depreciation and amortization shown below)550,891582,756
Selling, research & development and administrative155,277152,780
Depreciation and amortization65,64764,349
Restructuring initiatives2,0423,480
Total Operating Expenses773,857803,365
Operating Income113,448112,083
Other (Expense) Income:

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is AptarGroup's D&A?
AptarGroup (ATR) reported D&A of $65.65M in Q1 2025.
How has AptarGroup's D&A changed year-over-year?
AptarGroup's D&A increased by 2.0% year-over-year, from $64.35M to $65.65M.
What is the long-term trend for AptarGroup's D&A?
Over 3 years (2021 to 2024), AptarGroup's D&A has grown at a 3.9% compound annual growth rate (CAGR), from $234.85M to $263.78M.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Ask your AI about AptarGroup's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude